Guangzhou Trinomab Biotech Co., Ltd. Report issue

Government Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2016
NCT02709616
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Trinomab Biotech Co., Ltd. | Zhuhai Trinomab Pharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (3)

tetanus immunoglobulin (Bastet) (1 trial)

tnm001 (2 trials)

tnm002 (4 trials)

Drugs in Phase 2 Trials (2)

htig (1 trial)

percellvac (3 trials)

Drugs in Phase 1 Trials (2)

tnm005 (1 trial)

varicella zoster immune globulin (human) (varizig) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 7